UBS AM’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-130,191
| Closed | -$6.83M | – | 2629 |
|
|
2020
Q3 | $6.83M | Sell |
130,191
-242,491
| -65% | -$10M | ﹤0.01% | 1051 |
|
|
2020
Q2 | $12.4M | Buy |
372,682
+35,886
| +11% | +$1.14M | 0.01% | 856 |
|
|
2020
Q1 | $9.16M | Sell |
336,796
-114,245
| -25% | -$3.18M | 0.01% | 884 |
|
|
2019
Q4 | $8.9M | Buy |
451,041
+380,986
| +544% | +$6.09M | 0.01% | 985 |
|
|
2019
Q3 | $908K | Buy |
70,055
+10,261
| +17% | +$124K | ﹤0.01% | 2006 |
|
|
2019
Q2 | $744K | Buy |
59,794
+9,876
| +20% | +$131K | ﹤0.01% | 2029 |
|
|
2019
Q1 | $725K | Buy |
49,918
+8,215
| +20% | +$105K | ﹤0.01% | 1949 |
|
|
2018
Q4 | $460K | Sell |
41,703
-1,258
| -3% | -$17.5K | ﹤0.01% | 2026 |
|
|
2018
Q3 | $1.13M | Buy |
42,961
+1,145
| +3% | +$31K | ﹤0.01% | 1766 |
|
|
2018
Q2 | $855K | Buy |
41,816
+9,805
| +31% | +$210K | ﹤0.01% | 1882 |
|
|
2018
Q1 | $581K | Buy |
32,011
+3,515
| +12% | +$58.6K | ﹤0.01% | 1976 |
|
|
2017
Q4 | $398K | Hold |
28,496
| – | – | ﹤0.01% | 2045 |
|
|
2017
Q3 | $527K | Buy |
28,496
+502
| +2% | +$8.39K | ﹤0.01% | 1928 |
|
|
2017
Q2 | $473K | Buy |
27,994
+5,744
| +26% | +$87.4K | ﹤0.01% | 1900 |
|
|
2017
Q1 | $297K | Buy |
22,250
+12,151
| +120% | +$190K | ﹤0.01% | 2019 |
|
|
2016
Q4 | $152K | Sell |
10,099
-22,800
| -69% | -$301K | ﹤0.01% | 2192 |
|
|
2016
Q3 | $385K | Hold |
32,899
| – | – | ﹤0.01% | 2129 |
|
|
2016
Q2 | $355K | Hold |
32,899
| – | – | ﹤0.01% | 2146 |
|
|
2016
Q1 | $304K | Sell |
32,899
-2,400
| -7% | -$25.8K | ﹤0.01% | 2209 |
|
|
2015
Q4 | $524K | Buy |
35,299
+3,200
| +10% | +$53.5K | ﹤0.01% | 2023 |
|
|
2015
Q3 | $527K | Sell |
32,099
-4,600
| -13% | -$94.2K | ﹤0.01% | 1993 |
|
|
2015
Q2 | $837K | Buy |
36,699
+13,100
| +56% | +$261K | ﹤0.01% | 1768 |
|
|
2015
Q1 | $359K | Buy |
23,599
+4,500
| +24% | +$58.5K | ﹤0.01% | 2158 |
|
|
2014
Q4 | $230K | Hold |
19,099
| – | – | ﹤0.01% | 2397 |
|
|
2014
Q3 | $217K | Hold |
19,099
| – | – | ﹤0.01% | 2325 |
|
|
2014
Q2 | $231K | Hold |
19,099
| – | – | ﹤0.01% | 2335 |
|
|
2014
Q1 | $223K | Hold |
19,099
| – | – | ﹤0.01% | 2377 |
|
|
2013
Q4 | $338K | Sell |
19,099
-1,300
| -6% | -$21.8K | ﹤0.01% | 2046 |
|
|
2013
Q3 | $294K | Hold |
20,399
| – | – | ﹤0.01% | 2092 |
|
|
2013
Q2 | $307K | Buy |
+20,399
| New | +$269K | ﹤0.01% | 1978 |
|
UBS AM's MNTA Position: Q4 2020 in Review
UBS AM sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 130,191 shares — an estimated $6.83M sold.
UBS AM first reported a position in MNTA in Q2 2013 and held it in 30 quarters. The position peaked at $12.4M in Q2 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- UBS AM reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- UBS AM sold 130,191 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $6.83M.
- UBS AM first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 30 quarters.
- UBS AM's Momenta Pharmaceuticals, Inc. position peaked at $12.4M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on UBS AM's 13F filing for Q4 2020, filed 17 Feb 2021.